Dosage & Administration
Prior to initiating treatment with methylphenidate hydrochloride extended-release tablets, assess for the presence of ______ disease.
What is cardiac?
(Section 2.1)
In pediatric patients, age 6 to 12 years, the Methylphenidate hydrochloride extended-release tablets Recommended Starting Dosage is ____mg, once daily.
What is 18?
(Table 1)
The Trigen version of Methylphenidate hydrochloride extended-release tablets are available in the following strengths...
What are 18mg, 27mg, 36mg, 45mg, 54mg, 63mg and 72mg?
(Section 3)
Methylphenidate hydrochloride extended-release tablets are contraindicated in patients with a known ________ to methylphenidate or other components of methylphenidate hydrochloride extended-release tablets.
What is hypersensitivity?
(Section 4)
Methylphenidate hydrochloride extended-release tablets use _____ _____ to deliver methylphenidate hydrochloride at a controlled rate.
What is osmotic pressure?
(Section 11)
Assess the risk of abuse prior to prescribing and monitor for signs of _______ ___ ________ while on therapy.
What is abuse and dependence?
(Section 2.1)
In adult patients, 18 (up to 65 years) years, the Methylphenidate hydrochloride extended-release tablets Recommended Starting Dosage is ____mg or ___mg, once daily.
What is 18 or 36?
(Table 1)
Trigen methylphenidate ER 45mg tablets are _____, in color.
What is pink?
(Section 3)
Methylphenidate hydrochloride extended-release tablets are contraindicated in patients receiving concomitant treatment with _____ _____ _____, and also within 14 days following discontinuation of treatment with a _____ _____ _____, because of the risk of hypertensive crisis. (Same answer in both)
What are monoamine oxidase inhibitors (MAOIs)?
(Section 4)
The ______ system, which resembles a conventional tablet in appearance, comprises an osmotically active bilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat.
What is Osmodex® (drug delivery)?
(Section 11)
Administer methylphenidate hydrochloride extended-release tablets orally once daily __ ___ _____ with or without food.
What is in the morning?
(Section 2.2)
In pediatric patients, age 6 to 12 years, the Methylphenidate hydrochloride extended-release tablets Dosage Range is ____mg to ___mg, once daily.
What is 18 to 54?
(Table 1)
Trigen methylphenidate ER 63mg tablets are _____, in color.
What is orange?
(Section 3)
CNS stimulants have been associated with weight loss and ______ of growth rate in pediatric patients.
What is slowing?
(Section 5.7)
Following oral administration of methylphenidate hydrochloride extended-release tablets plasma methylphenidate concentrations increase rapidly, reaching an initial maximum at about ___ _____.
What is 1.5 hours?
(Section 12.3)
Swallow methylphenidate hydrochloride extended-release tablets _____ with liquid. Do not chew, divide, or crush
What is whole?
(Section 2.2)
In pediatric patients, age 13 to 17 years, the Methylphenidate hydrochloride extended-release tablets Dosage Range is ____mg to ___mg, once daily.
What is 18 to 72? (not to exceed 2mg/kg/day)
(Table 1)
Trigen methylphenidate ER 72mg tablets are _____, in color.
What is blue?
(Section 3)
Methylphenidate hydrochloride extended-release tablets may _______ the effectiveness of drugs used to treat hypertension
What is decrease?
(Table 6)
Mean time to reach peak plasma concentrations of methylphenidate hydrochloride extended-release tablets occurs at ___ _____.
What is 5.5 hours?
(Section 12.3)
Doses may be increased in 18 mg increments at ______ intervals for patients who have not achieved clinical response at a lower dose.
What is weekly?
(Section 2.5)
In adult patients, 18 (up to 65 years), the Methylphenidate hydrochloride extended-release tablets Dosage Range is ____mg to ___mg, once daily.
What is 18 to 72?
(Table 1)
According to the methylphenidate ER medication guide, methylphenidate hydrochloride extended-release tablets should be stored at room temperature between ___ __ ___.
What is 68°F to 77°F(20°C to 25°C)?
(Section 16)
Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of ______ ______.
What are extrapyramidal symptoms (EPS)?
(Table 6)
There is no evidence of ____ _____ in the presence or absence of food.
What is dose dumping? (Section 12.3)
(Dose dumping refers to the phenomenon that happens when an extended-release drug enters the body too rapidly. Some drugs are labeled as having a slow-release rate, they have the potential to release rapidly with the introduction of certain environmental factors.)